Zacks Investment Research upgraded shares of Celsion (NASDAQ:CLSN) from a sell rating to a hold rating in a research report report published on Tuesday morning.
According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
Several other analysts have also recently weighed in on the company. ValuEngine upgraded Celsion from a hold rating to a buy rating in a report on Thursday, November 1st. Oppenheimer set a $9.00 price target on Celsion and gave the stock a buy rating in a report on Thursday, November 15th. Finally, Brookline Cap M restated a buy rating on shares of Celsion in a report on Tuesday, November 20th.
Celsion stock opened at $2.12 on Tuesday. Celsion has a 12-month low of $1.68 and a 12-month high of $3.48. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.62.
Celsion (NASDAQ:CLSN) last released its quarterly earnings results on Thursday, November 15th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.04). The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 104.30% and a negative net margin of 4,282.33%. Analysts anticipate that Celsion will post -1.34 earnings per share for the current year.
A hedge fund recently raised its stake in Celsion stock. Vanguard Group Inc. lifted its position in shares of Celsion Co. (NASDAQ:CLSN) by 40.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 740,132 shares of the biotechnology company’s stock after purchasing an additional 214,829 shares during the period. Vanguard Group Inc. owned about 3.95% of Celsion worth $2,050,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 6.29% of the company’s stock.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.
Featured Story: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.